stockportfolio.pro
ASP Isotopes Inc. (ASPI)
Basic Materials · Chemicals · NasdaqCM
ASP Isotopes Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $433,026 | $4.14M | $23.85M |
| Gross profit | — | $138,970 | $1.60M | $3.40M |
| Net income | $-4.95M | $-16.29M | $-32.33M | $-175.09M |
| Net margin | — | -3761.0% | -780.3% | -734.2% |
Source: ASP Isotopes Inc. SEC filings (10-K).
Explore 4 years of ASP Isotopes Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ASPI in your portfolio →
ASP Isotopes Inc. financial history by metric
About ASP Isotopes Inc.
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
ASP Isotopes Inc. — frequently asked questions
What is ASP Isotopes Inc.'s revenue?
ASP Isotopes Inc. (ASPI) reported revenue of $23.85M for fiscal year 2025, up 475.5% from the prior year, according to its SEC filings.
Is ASP Isotopes Inc. profitable?
No — ASPI reported a net loss of $-175.09M in fiscal 2025.
What is ASPI's P/E ratio?
ASP Isotopes Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does ASP Isotopes Inc. have?
As of fiscal year 2025, ASPI carried roughly $213.68M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ASP Isotopes Inc.'s gross margin?
ASPI's gross margin was 14.3% in fiscal 2025 — gross profit of $3.40M on revenue of $23.85M.
What is ASP Isotopes Inc.'s market cap?
ASP Isotopes Inc. (ASPI) has a market capitalization of about $757.31M, based on the latest data in our nightly-refreshed cache.
When does ASP Isotopes Inc.'s fiscal year end?
ASPI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ASP Isotopes Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.